SANOFI - DUPIXENT RECEIVES US APPROVAL FOR TREATMENT OF NINE DIFFERENT CONDITIONS ASSOCIATED WITH TYPE 2 INFLAMMATION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy SNY?
Source: moomoo
Approval of Sanofi Dupixent: Sanofi's Dupixent has been approved in the U.S. for the treatment of nine distinct diseases.
Focus on Type 2 Inflammation: The approval is particularly significant for conditions driven in part by type 2 inflammation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.660
Low
57.00
Averages
79.36
High
119.07
Current: 47.660
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi's Rilzabrutinib Receives Orphan Drug Designation in Japan
- Orphan Drug Designation: Sanofi's rilzabrutinib has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for the treatment of IgG4-related disease, marking a significant expansion in the company's rare disease portfolio and expected to enhance market competitiveness.
- Clinical Research Progress: Rilzabrutinib is currently being evaluated in the RILIEF phase 3 study focused on IgG4-RD, and successful clinical outcomes will lay the groundwork for future market promotion and adoption.
- International Approval Status: The drug received approval for immune thrombocytopenia in the US, EU, and UAE in 2025, demonstrating broad global recognition and further strengthening Sanofi's product portfolio.
- Regulatory Review Updates: Rilzabrutinib is under regulatory review for ITP in Japan, and if approved, it will provide a new growth avenue for the company in the Japanese market, enhancing overall performance.
See More
Sino Biopharmaceutical Licenses Blood Cancer Drug to Sanofi for Up to $1.53B
- Agreement Reached: Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has signed an exclusive licensing agreement with Sanofi for the blood cancer drug rovadicitinib, with a total deal value of up to $1.53 billion, highlighting Sino's strategic positioning in the global market.
- Upfront and Milestone Payments: Sino Biopharmaceutical is set to receive $135 million upfront, along with milestone payments that could reach $1.395 billion, reflecting the significant value of the drug's development and market potential.
- Royalty Structure: Chia Tai Tianqing will receive a tiered royalty of a double-digit percentage based on the annual net sales of rovadicitinib, which will provide a continuous revenue stream and enhance the company's financial stability.
- Drug Approval and Market Outlook: Rovadicitinib was approved by Chinese regulators last month as a first-line treatment for adults with a rare blood cancer, and the U.S. has also approved mid-stage trials for chronic graft-versus-host disease, indicating a promising international market outlook for the drug.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Teva Pharmaceutical Stock Doubles, Strong Outlook Ahead
- Earnings Beat: Teva Pharmaceutical reported fourth-quarter revenue of $4.7 billion for 2025, an 11% year-over-year increase, with adjusted EPS at $0.96, significantly surpassing the analyst forecast of $0.64, indicating robust financial performance and market demand.
- Strategic Shift: Teva is pivoting from generic drugs to specialty pharmaceuticals, with strong sales from branded drugs like Austedo, Ajovy, and Uzedy offsetting flat generic sales, and these products are expected to comprise a larger share of revenue, enhancing overall profitability.
- Future Growth Potential: Management anticipates that the drug candidate duvakitug could achieve peak annual sales of $2 billion to $5 billion, and with other pipeline candidates, the total sales potential exceeds $10 billion, showcasing Teva's strong competitive position in the future market.
- Attractive Valuation: Currently trading at around 12.5 times forward earnings, Teva is positioned in the middle to lower end of the pharmaceutical valuation range, providing long-term investors an opportunity to enter before potential price appreciation, especially if the stock price dips.
See More
Japan Grants Orphan Drug Designation to Rilzabrutinib
- Orphan Drug Designation: The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to Rilzabrutinib for IgG4-related disease, a decision supported by positive Phase 2 study data, which is expected to expedite market access and enhance the company's competitiveness in the rare disease sector.
- Disease Context: IgG4-related disease is a progressive, relapsing, chronic immune-mediated rare disease with an estimated prevalence of about eight cases per 100,000 adults in Japan, potentially leading to organ damage and irreversible dysfunction if untreated, highlighting the urgent need for effective therapies.
- Clinical Study Results: In a 52-week treatment of IgG4-RD patients, Rilzabrutinib significantly reduced disease flares and other disease markers while minimizing the need for glucocorticoid treatment, demonstrating its potential therapeutic advantages and a favorable safety profile consistent with previous studies.
- Market Outlook: Rilzabrutinib received approval for the treatment of immune thrombocytopenia (ITP) in the US, EU, and UAE in 2025, and is currently under regulatory review for ITP in Japan, indicating its potential to play a significant role in treating multiple rare immune-mediated diseases in the future.
See More
Novavax Q4 2025 Financial Results Analysis
- Profit Shift: Novavax reported a fourth-quarter profit of $0.11, a significant turnaround from a loss of $0.51 a year ago, with revenue reaching $147 million, reflecting a 67% year-over-year increase, indicating improved profitability.
- Revenue Forecast Shortfall: Despite strong Q4 results, Novavax projected adjusted total revenue for 2026 between $230 million and $270 million, falling short of the consensus estimate of $381.22 million, which could negatively impact stock performance.
- R&D and SG&A Expenses: The company anticipates Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and less than $200 million in 2028, highlighting efforts in cost management but potentially affecting future profitability.
- Short-Term Market Performance: Currently, Novavax's stock is trading 8.4% above its 20-day and 9.2% above its 100-day simple moving averages, indicating short-term resilience despite recent downturns, prompting investors to watch for potential breakout or reversal signals.
See More
Sanofi's Rilzabrutinib Receives Orphan Drug Designation in Japan
- Orphan Drug Designation: Sanofi's rilzabrutinib has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for the treatment of IgG4-related disease, marking a significant expansion in the company's rare disease portfolio and expected to enhance market competitiveness.
- Clinical Research Progress: Rilzabrutinib is currently being evaluated in the RILIEF phase 3 study focused on IgG4-RD, and successful clinical outcomes will lay the groundwork for future market promotion and adoption.
- International Approval Status: The drug received approval for immune thrombocytopenia in the US, EU, and UAE in 2025, demonstrating broad global recognition and further strengthening Sanofi's product portfolio.
- Regulatory Review Updates: Rilzabrutinib is under regulatory review for ITP in Japan, and if approved, it will provide a new growth avenue for the company in the Japanese market, enhancing overall performance.
See More
Sino Biopharmaceutical Licenses Blood Cancer Drug to Sanofi for Up to $1.53B
- Agreement Reached: Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has signed an exclusive licensing agreement with Sanofi for the blood cancer drug rovadicitinib, with a total deal value of up to $1.53 billion, highlighting Sino's strategic positioning in the global market.
- Upfront and Milestone Payments: Sino Biopharmaceutical is set to receive $135 million upfront, along with milestone payments that could reach $1.395 billion, reflecting the significant value of the drug's development and market potential.
- Royalty Structure: Chia Tai Tianqing will receive a tiered royalty of a double-digit percentage based on the annual net sales of rovadicitinib, which will provide a continuous revenue stream and enhance the company's financial stability.
- Drug Approval and Market Outlook: Rovadicitinib was approved by Chinese regulators last month as a first-line treatment for adults with a rare blood cancer, and the U.S. has also approved mid-stage trials for chronic graft-versus-host disease, indicating a promising international market outlook for the drug.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Teva Pharmaceutical Stock Doubles, Strong Outlook Ahead
- Earnings Beat: Teva Pharmaceutical reported fourth-quarter revenue of $4.7 billion for 2025, an 11% year-over-year increase, with adjusted EPS at $0.96, significantly surpassing the analyst forecast of $0.64, indicating robust financial performance and market demand.
- Strategic Shift: Teva is pivoting from generic drugs to specialty pharmaceuticals, with strong sales from branded drugs like Austedo, Ajovy, and Uzedy offsetting flat generic sales, and these products are expected to comprise a larger share of revenue, enhancing overall profitability.
- Future Growth Potential: Management anticipates that the drug candidate duvakitug could achieve peak annual sales of $2 billion to $5 billion, and with other pipeline candidates, the total sales potential exceeds $10 billion, showcasing Teva's strong competitive position in the future market.
- Attractive Valuation: Currently trading at around 12.5 times forward earnings, Teva is positioned in the middle to lower end of the pharmaceutical valuation range, providing long-term investors an opportunity to enter before potential price appreciation, especially if the stock price dips.
See More
Japan Grants Orphan Drug Designation to Rilzabrutinib
- Orphan Drug Designation: The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to Rilzabrutinib for IgG4-related disease, a decision supported by positive Phase 2 study data, which is expected to expedite market access and enhance the company's competitiveness in the rare disease sector.
- Disease Context: IgG4-related disease is a progressive, relapsing, chronic immune-mediated rare disease with an estimated prevalence of about eight cases per 100,000 adults in Japan, potentially leading to organ damage and irreversible dysfunction if untreated, highlighting the urgent need for effective therapies.
- Clinical Study Results: In a 52-week treatment of IgG4-RD patients, Rilzabrutinib significantly reduced disease flares and other disease markers while minimizing the need for glucocorticoid treatment, demonstrating its potential therapeutic advantages and a favorable safety profile consistent with previous studies.
- Market Outlook: Rilzabrutinib received approval for the treatment of immune thrombocytopenia (ITP) in the US, EU, and UAE in 2025, and is currently under regulatory review for ITP in Japan, indicating its potential to play a significant role in treating multiple rare immune-mediated diseases in the future.
See More
Novavax Q4 2025 Financial Results Analysis
- Profit Shift: Novavax reported a fourth-quarter profit of $0.11, a significant turnaround from a loss of $0.51 a year ago, with revenue reaching $147 million, reflecting a 67% year-over-year increase, indicating improved profitability.
- Revenue Forecast Shortfall: Despite strong Q4 results, Novavax projected adjusted total revenue for 2026 between $230 million and $270 million, falling short of the consensus estimate of $381.22 million, which could negatively impact stock performance.
- R&D and SG&A Expenses: The company anticipates Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and less than $200 million in 2028, highlighting efforts in cost management but potentially affecting future profitability.
- Short-Term Market Performance: Currently, Novavax's stock is trading 8.4% above its 20-day and 9.2% above its 100-day simple moving averages, indicating short-term resilience despite recent downturns, prompting investors to watch for potential breakout or reversal signals.
See More
